English	French	Notes	Complete/Exclude
 59. WAS ENTIRE SPECIMEN SUBMITTED			
     TO PATHOLOGY..................: NA			
 60. IF MARGINS ARE FREE, WHAT IS			
     THE DISTANCE..................: NA			
     TO PATHOLOGY..................: Unknown			
     THE DISTANCE..................: Unknown			
948 59. WAS ENTIRE SPECIMEN SUBMITTED                                                   TO PATHOLOGY..................			
949 60. IF MARGINS ARE FREE, WHAT IS                                                    THE DISTANCE..................			
 61. SCOPE OF REGIONAL LYMPH NODE			
 62. NUMBER OF REGIONAL LYMPH NODES			
 63. SURGERY OF OTHER REGIONAL			
     SITE(S), DISTANT SITE(S),			
     OR DISTANT LYMPH NODE(S)......: 			
 66. MICROSCOPIC STATUS OF FINAL			
     MARGIN AFTER RESECTION........: NA			
     MARGIN AFTER RESECTION........: Unknown			
     MARGIN AFTER RE-EXCISION......: NA			
     MARGIN AFTER RE-EXCISION......: Unknown			
951 66. MICROSCOPIC STATUS OF FINAL                                                     MARGIN AFTER RE-EXCISION......			
 GO TO ITEM: 			
 RADIATION THERAPY			
 67. RADIATION THERAPY.............: 			
 68. PRE-RADIATION THERAPY			
     MAMMOGRAM OF PATIENT..........: Not done			
     MAMMOGRAM OF PATIENT..........: Unknown if done			
952 68. PRE-RADIATION THERAPY                                                           MAMMOGRAM OF PATIENT..........			
 69. DATE RADIATION STARTED........: 			
 70. DATE RADIATION ENDED..........: 			
 71. SITES IRRADIATED..............: 			
 72. (F) cGy DOSE TO WHOLE BREAST			
     OR CHEST WALL.................: 			
 73. (F) BOOST RADIATION...........: 			
361 70. DATE RADIATION ENDED..........			
953 71. SITES IRRADIATED..............			
     OR CHEST WALL.................: (Data Item for Females Only)			
 73. (F) BOOST RADIATION...........: (Data Item for Females Only)			
954 72. (F) cGy DOSE TO WHOLE BREAST                                                    OR CHEST WALL.................			
443 73. (F) BOOST RADIATION...........			
 74. REASON FOR NO RADIATION ......: 			
 HORMONE THERAPY			
 75. HORMONE THERAPY...............: 			
 76. DATE HORMONE THERAPY STARTED..: 			
 77. (M) SPECIFIC HORMONE THERAPY..: (Data Item for Males Only)			
 77. (M) SPECIFIC HORMONE THERAPY...: None			
 77. (M) SPECIFIC HORMONE THERAPY...: Unknown			
955 77. (M) SPECIFIC HORMONE THERAPY..			
 79. DATE CHEMOTHERAPY STARTED.....: 			
 80. CHEMOTHERAPEUTIC REGIME			
     CONTAINING DOXORUBICIN.......: NA, no chemotherapy			
     CONTAINING DOXORUBICIN.......: Unknown			
956 80. CHEMOTHERAPEUTIC REGIME                                                         CONTAINING DOXORUBICIN........			
81. DATE OF FIRST RECURRENCE			
82. TYPE OF FIRST RECURRENCE			
81. TYPE OF FIRST RECURRENCE			
82. DATE OF FIRST RECURRENCE			
 TABLE VI - FIRST RECURRENCE			
70 81. DATE OF FIRST RECURRENCE			
71 82. TYPE OF FIRST RECURRENCE			
83. DATE OF LAST CONTACT OR DEATH			
84. VITAL STATUS			
85. CANCER STATUS			
86. COMPLETED BY			
87. REVIEWED BY CANCER COMMITTEE			
 TABLE VII - STATUS AT LAST CONTACT			
 83. DATE OF LAST CONTACT OR DEATH..: 			
15 84. VITAL STATUS...................			
 85. CANCER STATUS..................: 			
81 86. COMPLETED BY...................			
82 87. REVIEWED BY CANCER COMMITTEE...			
 1. INSTITUTION ID NUMBER............: H6			
 2. ACCESSION NUMBER.................: 			
 3. SEQUENCE NUMBER..................: 			
 4. POSTAL CODE AT DIAGNOSIS.........: 			
 5. DATE OF BIRTH....................: 			
 7. SPANISH ORIGIN...................: 			
 9. PRIMARY PAYER AT DIAGNOSIS.......: 			
10. FAMILY HISTORY OF BREAST CANCER:			
     MATERNAL AUNT...................: 			
     MATERNAL GRANDMOTHER............: 			
     ONE SISTER ONLY.................: 			
     MORE THAN ONE SISTER............: 			
     POSTIVE FAMILY HISTORY, NOS.....: 			
11. (F) PERSONAL HISTORY OF BREAST			
12. SYNCHRONOUS BREAST CANCER........: 			
13. PERSONAL HISTORY OF OTHER CANCER:			
14. (F) HORMONE REPLACEMENT THERAPY..: 			
15. (F) HOW MANY YEARS OF HORMONE			
    REPLACEMENT THERAPY..............: 			
TABLE II - INITIAL DIAGNOSIS			
16. CLASS OF CASE....................: 			
17. DIAGNOSTIC EVALUATION:			
18. (F) TYPE OF MAMMOGRAM:			
     A. MAMMOGRAM GIVEN, TYPE UNKNOWN: 			
     B. SCREENING MAMMOGRAM..........: 			
     C. DIAGNOSTIC MAMMOGRAM.........: 			
     D. MAGNIFICAITON MAMMOGRAM......: 			
19. (F) PRESENTATION OF MOST			
    DEFINITIVE MAMMOGRAM.............: 			
20. DATE OF INITIAL DIAGNOSIS........: 			
21. DATE OF PATHOLOGIC DIAGNOSIS.....: 			
22. PRIMARY SITE (ICD-O-2)...........: 			
24. BEHAVIOR CODE (ICD-O-2)..........: 			
25. IF INVASIVE DUCTUAL CARCINOMA			
    REPORTED, IS DCIS ALSO PRESENT...: 			
27. ARCHITECTURE PATTERN IF DCIS			
    IS PRESENT.......................: 			
28. NUCLEAR GRADE IF DCIS IS			
29. DIAGNOSTIC CONFIRMATION..........: 			
30. (M) LEVEL OF INVOLVEMENT:			
     CHEST WALL......................: 			
     PECTORAL MUSCLES................: 			
    DIAGNOSTIC AND STAGING PROCEDURES			
31. BIOPSY PROCEDURE.................: 			
33. PALPABILITY OF PRIMARY...........: 			
34. FIRST DETECTED BY................: 			
TABLE III - TUMOR MARKERS AND PROGNOSTIC TESTS			
35. (M) DNA INDEX/PLOIDY.............: 			
36. ESTROGEN RECEPTOR PROTEIN........: 			
37. PROGESTERONE RECEPTOR PROTEIN....: 			
38. (M) ANDROGEN RECEPTOR PROTEIN....: 			
39. TYPE OF TEST.....................: 			
Print Breast Cancer PCE			
(Data Item for Females Only)			
(Data Item for Males Only)			
TABLE IV - EXTENT OF DISEASE AND AJCC STAGE			
40. SIZE OF TUMOR (mm)...............: 			
41. SIZE OF DCIS TUMOR (mm)..........: 			
42. REGIONAL NODES EXAMINED..........: 			
43. REGIONAL NODES POSITIVE..........: 			
    SENTINEL NODES			
44. SENTINEL NODES BIOPSY............: 			
45. NUMBER OF SENTINEL NODES			
46. NUMBER OF SENTINEL NODES			
47. SENTINEL NODE DETECTED BY........: 			
48. AJCC CLINICAL STAGE (cTNM):			
     AJCC STAGE......................: 			
49. AJCC PATHOLOGIC STAGE (pTNM):			
50. STAGED BY:			
     CLINICAL STAGE..................: 			
     PATHOLOGIC STAGE................: 			
TABLE V - FIRST COURSE OF TREATMENT			
51. DATE OF FIRST COURSE TREATMENT...: 			
52. DATE OF NON CANCER-DIRECTED			
53. NON CANCER-DIRECTED SURGERY......: 			
54. DATE OF (FIRST) CANCER-			
    DIRECTED SURGERY.................: 			
55. SURGICAL APPROACH................: 			
56. SURGERY OF PRIMARY SITE..........: 			
57. SPECIMEN RADIOGRAPH..............: 			
58. SURGICAL MARGINS.................: 			
59. WAS ENTIRE SPECIMEN SUBMITTED			
    TO PATHOLOGY.....................: 			
60. IF MARGINS ARE FREE, WHAT IS			
    THE DISTANCE.....................: 			
61. SCOPE OF REGIONAL LYMPH NODE			
62. NUMBER OF REGIONAL LYMPH NODES			
63. SURGERY OF OTHER REGIONAL			
    SITE(S), DISTANT SITE(S),			
    OR DISTANT LYMPH NODE(S).........: 			
66. MICROSCOPIC STATUS OF FINAL			
    MARGIN AFTER RE-EXCISION.........: 			
67. RADIATION THERAPY................: 			
68. PRE-RADIATION THERAPY			
    MAMMOGRAM OF PATIENT.............: 			
69. DATE RADIATION STARTED...........: 			
70. DATE RADIATION ENDED.............: 			
71. SITES IRRADIATED.................: 			
72. (F) cCy DOSE TO WHOLE BREAST			
    OR CHEST WALL....................: 			
73. BOOST RADIATION..................: 			
74. REASON FOR NOT RADIATION.........: 			
    HORMONE THERAPY			
75. HORMONE THERAPY..................: 			
76. DATE HORMONE THERAPY STARTED.....: 			
77. (M) SPECIFIC HORMONE THERAPY.....: 			
79. DATE CHEMOTHERAPY STARTED........: 			
80. CHEMOTHERAPEUTIC REGIME			
    CONTAINING DOXORUBICIN...........: 			
TABLE VI - FIRST RECURRENCE			
81. DATE OF FIRST RECURRENCE.........: 			
82. TYPE OF FIRST RECURRENCE.........: 			
TABLE VII - STATUS AT LAST CONTACT			
83. DATE OF LAST CONTACT OR DEATH....: 			
84. VITAL STATUS.....................: 			
85. CANCER STATUS....................: 			
86. COMPLETED BY.....................: 			
87. REVIEWED BY CANCER COMMITTEE.....: 			
The Accession Year is not 1997.			
The Diagnostic Confirmation code is not 1, 2 or 4.			
There is no HISTOLOGY for this primary.			
The BEHAVIOR code is not 2 (in situ) or 3 (malignant).			
The Histology of 			
 is not eligible.			
9:Print Colorectal Cancer PCE			
Patient Care Evaluation Study of Colorectal Cancer			
ACCESSION NUMBER			
SEQUENCE NUMBER			
POSTAL CODE AT DIAGNOSIS			
FAMILY HISTORY OF COLORECTAL CANCER			
PERSONAL HISTORY OF COLORECTAL CANCER			
MULTIPLE COLON/RECTUM PRIMARIES 1997			
PERSONAL HISTORY OF NON-COLORECTAL CANCER			
PREVIOUS TAH/BSO			
OTHER PRIOR CONDITIONS			
ACCESSION NUMBER.....................: 			
SEQUENCE NUMBER......................: 			
9POSTAL CODE AT DIAGNOSIS.............			
DATE OF BIRTH........................: 			
9SPANISH ORIGIN.......................			
18PRIMARY PAYER AT DIAGNOSIS...........			
700FAMILY HISTORY OF COLORECTAL CANCER..			
701PERSONAL HISTORY OF COLORECTAL CANCER			
702MULTIPLE COLON/RECTUM PRIMARIES 1997.			
PERSONAL HISTORY OF NON-COLORECTAL CANCER:			
706  OVARIAN CARCINOMA, PERITONEAL SITE.			
710PREVIOUS TAH/BSO.....................			
OTHER PRIOR CONDITIONS:			
714  PRIOR POLYPS.......................			
DURATION OF SIGNS/SYMPTOMS PRESENT AT INITIAL DIAGNOSIS (months)			
INITIAL METHODS OF DIAGNOSIS			
REASON LEADING TO EVENTUAL DX			
DIAGNOSTIC EVALUATION			
LEVEL OF TUMOR BY ENDOSCOPIC EXAM			
LEVEL OF RECTAL TUMOR			
PRIMARY SITE			
HISTOLOGY/BEHAVIOR CODE			
DIAGNOSTIC CONFIRMATION			
TABLE II- INITIAL DIAGNOSIS			
CLASS OF CLASS...................: 			
717  BOWEL OBSTRUCTION..............			
718  CHANGE IN BOWEL HABIT..........			
719  EMER PRESENTATION-OBSTRUCTION..			
722  OCCULT BLOOD ONLY IN STOOL.....			
725  RECTAL BLEEDING (MELENA).......			
INITIAL METHODS OF DIAGNOSIS:			
729  SCREENING DIGITAL RECTAL EXAM..			
730  SCREENING PHYSICAL EXAM........			
732REASON LEADING TO EVENTUAL DX....			
DIAGNOSTIC EVALUATION:			
733  BARIUM ENEMA, DOUBLE CONTRAST..			
734  BARIUM ENEMA, SINGLE CONTRAST..			
735  BARIUM ENEMA, NOS..............			
736  BIOPSY OF PRIMARY SITE.........			
737  BIOPSY OF METASTATIC SITE......			
421  CT SCAN OF CHEST...............			
738  CT SCAN OF LIVER...............			
739  CT SCAN OF PRIMARY SITE........			
741  CHEST ROENTGENOGRAM............			
743  DIGITAL RECTAL EXAM............			
744  FLEXIBLE SIGMOIDOSCOPY.........			
745  INTRAVENOUS PYELOGRAM (IVP)....			
746  SERUM-LIVER FUNCTION TEST......			
749  STOOL GUAIAC (OCCULT BLOOD)....			
752LEVEL OF TUMOR BY ENDOSCOPIC EXAM			
753LEVEL OF RECTAL TUMOR............			
PRIMARY SITE.....................: 			
HISTOLOGY/BEHAVIOR CODE..........: 			
26DIAGNOSTIC CONFIRMATION..........			
SIZE OF TUMOR (mm)			
CLINICAL STAGED BY			
PATHOLOGIC STAGED BY			
MARGIN OF RESECTION			
DISTANCE TO CLOSEST MUCOSAL MARGIN			
DISTANCE TO CLOSEST RADIAL MARGIN			
BLOOD VESSEL OR LYMPHATIC INVASION			
EXTRAMURAL VENOUS INVASION			
PROMINENT LYMPHOID INFILTRATE			
29SIZE OF TUMOR (mm).............			
38  AJCC STAGE...................			
19  CLINICAL STAGED BY...........			
88  AJCC STAGE...................			
89  PATHOLOGIC STAGED BY.........			
MARGIN OF RESECTION:			
754  PROXIMAL MARGIN..............			
755  DISTAL MARGIN................			
756  RADIAL MARGIN................			
757DISTANCE TO MUCOSAL MARGIN.....			
758DISTANCE TO RADIAL MARGIN......			
759BLOOD VESSEL/LYMPHATIC INVASION			
760EXTRAMURAL VENOUS INVASION.....			
761PROMINENT LYMPHOID INFILTRATE..			
PHYSICIAN PROVIDING TREATMENT			
DATE OF FIRST COURSE TREATMENT			
DATE OF INPATIENT ADMISSION			
DATE OF INPATIENT DISCHARGE			
762PHYSICIAN PROVIDING TREATMENT.....			
DATE OF FIRST COURSE TREATMENT....: 			
1DATE OF INPATIENT ADMISSION.......			
1.1DATE OF INPATIENT DISCHARGE.......			
  NON CANCER-DIRECTED SURGERY DATE: 			
  NON CANCER-DIRECTED SURGERY.....: 			
  SURGERY OF PRIMARY SITE DATE....: 			
  SURGERY OF PRIMARY SITE.........: 			
  ADDITIONAL SURGICAL PROCEDURES..: NA, none performed			
  LAPAROSCOPY USED DURING SURGERY.: NA			
  METHOD OF ANASTOMOSIS...........: Not done			
  DIST OF ANASTOMOSIS FROM DENTATE: 0			
  RESIDUAL PRIMARY TUMOR..........: NA			
  OTHER SURGERY:			
    PATHOLOGICAL STATUS...........: NA			
  COMPLICATIONS AFTER FIRST COURSE OF TREATMENT:			
####################	####################	####################	
####################	####################	####################	
####################	####################	####################	
####################	####################	####################	
####################	####################	####################	
